Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $28.12, but opened at $26.59. Chugai Pharmaceutical shares last traded at $27.48, with a volume of 11,249 shares changing hands.

Analysts Set New Price Targets

Separately, UBS Group raised shares of Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Chugai Pharmaceutical Trading Down 0.1%

The stock’s 50 day moving average is $26.77 and its two-hundred day moving average is $24.42. The stock has a market capitalization of $93.96 billion, a price-to-earnings ratio of 35.69 and a beta of 0.63.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Thursday, January 29th. The company reported $0.25 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 20.63% and a net margin of 32.74%.The company had revenue of $2.25 billion for the quarter. On average, research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.